SEI Investments’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-13,031
| Closed | -$940K | – | 3313 |
|
|
2025
Q4 | $940K | Sell |
13,031
-60,332
| -82% | -$3.9M | ﹤0.01% | 2211 |
|
|
2025
Q3 | $3.2M | Buy |
73,363
+17,684
| +32% | +$715K | ﹤0.01% | 1495 |
|
|
2025
Q2 | $1.58M | Buy |
55,679
+1,110
| +2% | +$33.1K | ﹤0.01% | 1743 |
|
|
2025
Q1 | $1.61M | Buy |
54,569
+33,015
| +153% | +$1.03M | ﹤0.01% | 1719 |
|
|
2024
Q4 | $627K | Sell |
21,554
-19,149
| -47% | -$800K | ﹤0.01% | 2106 |
|
|
2024
Q3 | $1.87M | Sell |
40,703
-3,018
| -7% | -$131K | ﹤0.01% | 1716 |
|
|
2024
Q2 | $1.79M | Buy |
43,721
+7,086
| +19% | +$203K | ﹤0.01% | 1684 |
|
|
2024
Q1 | $935K | Buy |
36,635
+4,881
| +15% | +$76.5K | ﹤0.01% | 1910 |
|
|
2023
Q4 | $287K | Hold |
31,754
| – | – | ﹤0.01% | 2322 |
|
|
2023
Q3 | $203K | Hold |
31,754
| – | – | ﹤0.01% | 2429 |
|
|
2023
Q2 | $352K | Sell |
31,754
-3,210
| -9% | -$40.3K | ﹤0.01% | 2269 |
|
|
2023
Q1 | $537K | Buy |
34,964
+14,471
| +71% | +$318K | ﹤0.01% | 2104 |
|
|
2022
Q4 | $455K | Buy |
20,493
+10,294
| +101% | +$153K | ﹤0.01% | 2048 |
|
|
2022
Q3 | $167K | Buy |
+10,199
| New | +$195K | ﹤0.01% | 2492 |
|
Other funds holding RNAM
SEI Investments's RNAM Position: Q1 2026 in Review
SEI Investments sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 13,031 shares — an estimated $940K sold.
SEI Investments first reported a position in RNAM in Q3 2022 and held it in 14 quarters. The position peaked at $3.2M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- SEI Investments reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- SEI Investments sold 13,031 Avidity Biosciences shares in Q1 2026, an estimated $940K.
- SEI Investments first reported a position in Avidity Biosciences in Q3 2022 and held it in 14 quarters.
- SEI Investments's Avidity Biosciences position peaked at $3.2M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.